Results of PREVENT III: A multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery

Recommended standards for reports dealing with lower extremity ischemia: Revised version

Robert B. Rutherford, J.Dennis Baker, Calvin B. Ernst et al. · Journal of Vascular Surgery · 1997 · 3.5K citations · Full text

Ischemic Stroke, Medicine, Patient Safety +11

Efficacy and Safety of Edifoligide, an E2F Transcription Factor Decoy, for Prevention of Vein Graft Failure Following Coronary Artery Bypass Graft Surgery

JAMA · 2005 · 657 citations

A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.

Ryuichi Morishita, Gary H. Gibbons, Masatsugu Horiuchi et al. · Proceedings of the National Academy of Sciences · 1995 · 482 citations · Full text

Immunology, Dna Technology, Transcription Factor Decoy +21

Present status of reversed vein bypass grafting: Five-year results of a modern series

Lloyd M. Taylor, James M. Edwards, John M. Porter · Journal of Vascular Surgery · 1990 · 449 citations

Present Status, Venous Disease, Endovascular Technique +7

Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial

Michael J. Mann, Anthony D. Whittemore, Magruder C. Donaldson et al. · The Lancet · 1999 · 400 citations

Translational Medicine, Gene Therapies, Transplantation +13